SEC Form 4 · accession 0001214659-15-007879
Anthera Pharmaceuticals Inc · ANTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Colin Hislop
Officer — Chief Medical Officer
Period of report
Nov 13, 2015
Accepted (ET)
Nov 18, 2015 · 6:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001316175
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 13, 2015 | M | 12,500 | $1.61 | A | 31,647 | D | |
| Common StockF2,F1 | Nov 13, 2015 | S | 12,500 | $5.3073 | D | 19,147 | D | |
| Common Stock | holding | — | — | — | 1,897 | I | By the Hislop-Burton Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock optionF3 | $1.61 | Dec 30, 2014 | M | 12,500 | D | — | Dec 30, 2024 | Common Stock | 12,500 | 107,500 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2015.
- F2The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.
- F3This stock option vests monthly over four years beginning December 30, 2014 (the Vesting Start Date). The Stock Option is completely vested on the fourth anniversary of the vesting start and will expire on December 30, 2024